An allogenic T cell immunotherapy proposed for treatment of relapsed or refractory Epstein-Barr virus-positive posttransplant lymphoproliferative disease.
An allogenic T cell immunotherapy proposed for treatment of relapsed or refractory Epstein-Barr virus-positive posttransplant lymphoproliferative disease.